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OBJECTIVES We sought to evaluate a simple risk index based on age and vital signs in a community sample
of patients with ST-segment elevation myocardial infarction (STEMI).
BACKGROUND A simple risk index based on age and vital signs (heart rate  [age/10]2/systolic blood
pressure) developed from patients with STEMI accurately predicts mortality in clinical trials
of fibrinolysis. The application of such a tool in an unselected population is necessary to
evaluate its utility in clinical practice.
METHODS To evaluate the Thrombolysis In Myocardial Infarction (TIMI) risk index for routine
practice, we tested it in the National Registry of Myocardial Infarction (NRMI)-3 and -4.
The risk index was evaluated as a continuous variable in patients with STEMI from NRMI
and in subgroups based on age and reperfusion status.
RESULTS A total of 153,486 patients with STEMI were eligible. As anticipated, STEMI patients in
NRMI had a higher risk index profile, as compared with those in the clinical trial (median
26.9 vs. 20, p  0.0001). Classification of NRMI patients with STEMI into risk groups
revealed a significant graded relationship with mortality (0.9% to 53.2%, ptrend  0.0001, c
statistic 0.79). The discriminatory capacity of the risk index was particularly strong in the
81,679 patients receiving reperfusion therapy (0.6% to 60%, ptrend  0.0001, c statistic 0.81).
For the 71,807 patients not receiving reperfusion therapy, a strong graded relationship
remained (1.9% to 52.2%, ptrend  0.0001, c statistic 0.71). Among the elderly, although the
distribution of scores was shifted toward higher risk, the performance remained (0% to 53.1%,
ptrend  0.0001, c statistic 0.71).
CONCLUSIONS A simple risk index from baseline clinical variables routinely obtained at the first patient
encounter predicted mortality in a large unselected heterogeneous group of patients with
STEMI. (J Am Coll Cardiol 2004;44:783–9) © 2004 by the American College of
Cardiology Foundationr
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sapid and accurate risk stratification by medical and para-
edical personnel is central to the initial management of
atients with suspected acute coronary syndromes (1).
See page 790
ultiple tools have been developed to assist with the
uantitative and qualitative assessment of risk among pa-
ients with acute coronary syndromes (2–13). These tools
ave been shown to predict the response to therapy (14–16).
An early in-hospital evaluation may assist with decisions
From the *TIMI Study Group, †Cardiovascular Division, Brigham and Women’s
ospital, Boston, Massachusetts; ‡Ovation Research, Seattle, Washington; and
Beth Israel Deaconess Medical Center, Boston, Massachusetts. The InTIME-II
tudy was supported by Bristol-Myers-Squibb (Princeton, New Jersey); Genentech
San Francisco, California) supported the National Registry of Myocardial Infarction.
Manuscript received October 22, 2003; revised manuscript received May 12, 2004,
ccepted May 18, 2004.egarding level of care and monitoring. Patients who are at
igh risk of adverse outcomes may benefit from initial triage
r early transfer to tertiary care centers (17). A prehospital
valuation of patients with myocardial infarction (MI) may
e strengthened by risk assessment to assist with triage
ecisions (18,19). A simple, generalizable, and practical risk
ndex for the rapid evaluation of patients with MI could
herefore prove valuable. Such a tool does not need to
apture all available prognostic information, but should
rovide an accurate preliminary estimate of risk.
The risk index, calculated using the equation: (heart rate
HR]  [age/10]2/systolic blood pressure [SBP]) (20), was
erived from 13,253 patients enrolled in the Intravenous
PA for Treatment of Infarcting Myocardium Early
InTIME-II) trial (21), a randomized trial of lanoteplase
ersus alteplase as reperfusion therapy (RT) for ST-segment
levation myocardial infarction (STEMI), and validated in a
econd clinical trial data set (20). The risk index offered
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TIMI Risk Index in NRMI August 18, 2004:783–9trong discrimination of mortality risk at 24 h, hospital
ischarge, and 30 days in the derivation set.
We sought to evaluate the performance of the Throm-
olysis In Myocardial Infarction (TIMI) risk index in a
eal-world setting. We therefore applied the TIMI risk
ndex to a nationally representative sample of patients
resenting to U.S. hospitals with STEMI in the National
egistry of Myocardial Infarction (NRMI)-3 and -4
22,23).
ETHODS
n the present analysis, evaluation of the risk index was
erformed in a community-based population from NRMI-3
nd -4. NRMI is an observational study of demographics,
ractice patterns, and health outcomes among patients with
I in the United States (22,23). Patient data from
RMI-3 (1,553 hospitals, April 1998 to June 2000) and
RMI-4 (1,272 hospitals, July 2000 to October 2002) were
ncluded. Compared with NRMI-3, patients in NRMI-4
ere slightly younger, and more patients in NRMI-4
eceived reperfusion, had primary percutaneous coronary
ntervention (PCI), and had slightly less frequent history of
oronary artery disease. As both sets of data represent recent
ractice patterns, data were combined in all analyses. All
anagement decisions were at the discretion of the treating
hysician.
Patients with ST-segment elevation or presumed new left
undle branch block were classified with STEMI. Patients
ere further classified as having received reperfusion therapy
STEMI-RT), including fibrinolytic or primary PCI. To
est for a difference in the performance of the index among
hose who received reperfusion, a logistic regression model
as created with terms for the risk index, reperfusion status,
nd the interaction of these two variables. As in the
nTIME-II trial, patients with complete data and a HR
etween 50 and 150 beats/min were included. Among
ontransfer patients with STEMI, 81% were eligible (8.4%
ere excluded for a nondiagnostic electrocardiogram, 4.9%
or HR 50 or 150 beats/min, 1.9% for cardiogenic
Abbreviations and Acronyms
CCP  Cardiovascular Cooperative Project
HR  heart rate
InTIME-II  Intravenous nPA for Treatment of
Infarcting Myocardium Early trial
IQR  interquartile range
MI  myocardial infarction
NRMI  National Registry of Myocardial
Infarction
PCI  percutaneous coronary intervention
RT  reperfusion therapy
SBP  systolic blood pressure
STEMI  ST-segment elevation myocardial
infarction
TIMI  Thrombolysis In Myocardial Infarctionhock, and 1.7% for missing SBP, HR, or age). pThe risk index was modeled as a continuous variable, and
0-point ranges are presented for reference. The prognostic
iscriminatory capacity of the risk index was expressed as
he c statistic, representing the area under the receiver
perator characteristics curve for prediction of in-hospital
eath (24). Differences in event rates across risk index
anges were assessed using the chi-square test for trend. To
urther evaluate the generalizability of the risk index, each
omponent of the risk index was examined individually and
n combination in both the InTIME-II trial and the
RMI, using logistic regression. A two-tailed p value
0.05 was considered significant. Statistical analyses were
erformed using SAS version 8.02 (SAS Institute, Cary,
orth Carolina).
ESULTS
total of 153,486 patients with STEMI were included. As
xpected, patients from NRMI were more likely to be older
nd female and have a history of congestive heart failure, MI
r revascularization, renal failure, and cerebrovascular acci-
ent, but less likely to be smokers, than those in the clinical
rial (InTIME-II) (Table 1). Of patients with STEMI in
RMI, 81,679 patients (53%) received early RT, with
2,239 (52% of these) treated with fibrinolytics and 39,440
48%) receiving primary PCI. There was an inverse rela-
ionship between the risk index and the proportion of
atients receiving RT, with 78% of patients with a risk
ndex of 0 to 10, 44% of patients with an index of 30 to 40,
nd 12% of patients with an index 80 treated with early
T. The baseline characteristics of the patients in NRMI
ho received early RT were similar to those of the
nTIME-II trial patients (Table 1). Compared with pa-
ients in NRMI receiving RT (STEMI-RT), the patients
ho did not (STEMI–no RT) were older, more often
emale, diabetic, and hypertensive, and more likely to have
history of renal failure, congestive heart failure, MI,
oronary artery bypass grafting, and stroke. Patients man-
ged without RT were more also more likely to have an
nterior MI.
Overall in-hospital mortality was higher in NRMI pa-
ients with STEMI (12.3%) than in the InTIME-II pa-
ients (5.4%). This difference was less pronounced for
atients with STEMI in NRMI treated with RT (6.6%) as
ompared with those who were managed without RT
18.7%).
There were different risk index distributions among the
tudy groups (Fig. 1). The clinical trial had a median of 20
interquartile range [IQR] 14 to 27). The median risk index
as higher in the registry patients (26.9 [IQR 17.5 to
0.4]), especially those who did not receive immediate RT
36.1 [IQR 24.5 to 50]) and the elderly (37.1 [IQR 28.2 to
9.3]). In addition to higher median risks, the patients who
id not receive RT were more likely to be in the highest risk
roups, with 42% of patients having an index 40, com-
ared with 11% of patients who received early RT. How-
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August 18, 2004:783–9 TIMI Risk Index in NRMIver, among NRMI patients who did receive RT (21 [IQR
4.7 to 30.3]), the median value and distribution were
imilar to those in the InTIME-II trial (Fig. 1).
Among patients with STEMI treated with RT, the risk
able 1. Baseline Characteristics
InTIME-II
(N  13,253)
ge (yrs) 61  12
65 (%) 41.9
75 (%) 13.4
emale (%) 24.8
eight (kg) 78  14
moker 45
iabetes 14.1
ypertension 30.4
enal failure 1.0
istory of CHF 3.1
istory of CVA 0.4
I 16
ngina 21.6
CI 4.4
ABG 2.7
nterior/LBBB 42.7
nferior 57.3
eart rate (beats/min) 76  18
BP (mm Hg) 139  22
edian TIMI risk score (25–75) (STEMI) 3 (1–4)
edian TRI (25–75) 20.0 (14–27)
ata are presented as the mean value  SD, percentage of subjects, or median valu
CABG  coronary artery bypass grafting; CHF  congestive heart failure; CVA
yocardium Early trial; LBBB  left bundle branch block; MI  myocardial infarc
ntervention; RT reperfusion therapy; SBP systolic blood pressure; STEMI ST
RI  TIMI risk index.
igure 1. Distribution of patients (%) in risk score categories. Lines with
InTIME-II) trial; lines with circles  ST-segment elevation myocardi
TEMI–no RT.ndex revealed a strong graded relationship with in-hospital
ortality (0.6% to 60%) across the risk index categories
ptrend  0.0001, c statistic 0.81) (Table 2). The observed
n-hospital mortality in each of the risk index groups was
NRMI
STEMI
(N  153,486)
STEMI–RT
(N  81,679)
STEMI–No RT
(N  71,807)
67.6  14.7 62.5  13.4 73.6  13.9
58.2 43.4 75.2
36.4 21.2 53.7
39.6 31.5 48.8
79.7  20.3 83.5  19.5 75.1  20.3
29.3 38.2 19.1
26.2 20.1 33.1
54.5 49.3 60.4
7.0 2.6 12.0
13.8 4.4 24.4
9.1 4.5 14.4
21.5 17.0 26.6
10.1 8.3 12.2
10.1 11.8 8.2
9.8 6.8 13.2
46.0 37.6 55.4
46.2 58.6 32.2
85.8  21.2 80  18.6 92.5  22
141.2  31.5 141.3  80.1 141.2  33
3 (1–5) 2.5 (1–4) 5 (3–6)
26.9 (17.5–40.4) 21.1 (14.7–30.3) 36.1 (24.5–50.0)
rquartile range).
rebrovascular accident; InTIMI-II  Intravenous nPA for Treatment of Infarcting
RMI  National Registry of Myocardial Infarction; PCI  percutaneous coronary
ent elevation myocardial infarction; TIMI Thrombolysis In Myocardial Infarction;
onds  Intravenous nPA for Treatment of Infarcting Myocardium Early
arction (STEMI)-reperfusion therapy (RT); and lines with triangles e (inte
 ce
tion; N
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TIMI Risk Index in NRMI August 18, 2004:783–9ighly concordant between NRMI and the InTIME-II trial
Fig. 2). The observed mortality rates in STEMI patients
rom NRMI treated without immediate RT (Table 2) were
igher than those in patients treated with reperfusion in
RMI (pinteraction  0.0001). Nevertheless, the risk index
aintained a significant graded association with in-hospital
ortality (1.9% to 52.2%, ptrend 0.001, c statistic 0.71). In
he elderly, there was also a strong graded relationship with
able 2. Relationship Between TIMI Risk Index and In-Hospita
Risk
Index
InTIME
(n  13,253)
STEMI
(n  153,486)
0 to 10 0.2 0.9
0 to 20 1.6 2.2
0 to 30 5.8 7.1
0 to 40 11.9 14.3
0 to 50 22.0 20.8
0 to 60 27.9 28.3
0 to 70 36.4 33.9
0 to 80 42.1 39.8
80 66.7 53.2
value 0.001 0.001
statistic 0.79 0.79
bbreviations as in Table 1.
igure 2. (A) Mortality (%) versus risk index in National Registry of M
nfarction (STEMI). HR  heart rate; SBP  systolic blood pressure. (B
nfarcting Myocardium Early (InTIME-II) trial (open bars) versus NRMI STn-hospital mortality (0% to 53.1%) across risk index groups
ptrend 0.0001, c statistic 0.71) (Table 2).
Evaluation of the individual components of the risk index
sing logistic regression showed similar associations with
ortality in NRMI and the InTIME-II trial (Table 3),
urther supporting the assertion that the these variables are
seful alone or in combination for risk stratification in a
eneral population with STEMI.
rtality (%)
STEMI–RT
(n  81,679)
STEMI–No RT
(n  71,807)
STEMI
>65 yrs of age
(n  89,385)
0.6 1.9 0.0
1.5 4.5 4.3
5.0 10.4 7.7
11.3 16.6 13.6
18.9 21.6 20.3
27.5 28.4 27.9
37.9 33.1 33.7
45.4 38.8 39.5
60 52.2 53.1
0.001 0.001 0.001
0.81 0.71 0.71
dial Infarction (NRMI) patients with ST-segment elevation myocardial
k index categories versus mortality in Intravenous nPA for Treatment ofl Moyocar
) RisEMI-reperfusion therapy (solid bars).
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August 18, 2004:783–9 TIMI Risk Index in NRMIISCUSSION
e applied a simple risk index derived in a clinical trial of
brinolytic therapy to a large, nationally representative
atabase of patients with MI. As a categorical indicator, this
ndex maintained a strong graded relationship with mortal-
ty in this unselected population with MI representative of
linical practice. Based on previous experience with risk
ssessment in large databases, it is not surprising that the
iscriminatory capacity of the risk index was strongest in
atients treated with RT (25). We have previously identified
ther factors such as medical co-morbidities that add to the
isk assessment among those treated without RT (25).
erformance of the risk index in NRMI. Multiple clas-
ification schemes have been developed and validated for the
urpose of risk stratification among patients with MI
2–8,10,13,20). Efforts have incorporated physiologic, lab-
ratory, and demographic data into integrative risk scores,
ncluding the TIMI risk scores for STEMI (8), unstable
ngina/non–ST-segment elevation MI (10), the PREDICT
core (4), and models derived from the Global Utilization of
treptokinase and TPA for Occluded arteries (GUSTO)
rial (6,7) and Platelet IIb/IIIa Underpinning the Receptor
or Suppression of Unstable Ischemia Trial (PURSUIT)
12).
In some cases, application of these tools requires detailed
edical evaluation, testing, and expertise to assess hemody-
amic, demographic, and laboratory features. Models that
nclude presenting data, specific laboratory testing, and
o-morbid illness are expected to have an increased discrim-
natory capacity (26). However, these models may not be
ractical for use in all situations, including initial in-hospital
ssessment or prehospital triage. The TIMI risk index has
he advantage that it retains much of the predictive capacity
f more complex systems, but can also be applied by both
edical and paramedical personnel with a minimum of
emographic (age) and physiologic information (HR and
BP). Additional data, including laboratory studies and
hysical examination, may be used later to update and refine
his initial risk assessment.
This index was initially derived and validated from
linical trial data (20). Patients who are enrolled in clinical
rials may have important differences from patients who are
ither ineligible or not enrolled (27,28). These differences
able 3. Odds Ratios for Mortality and Discriminative Capacity
c Statistic) for Individual Components of the Risk Index and
or the Index as a Continuous Variable
In TIME-II NRMI
OR c Statistic OR c Statistic
ge (10 yrs) 2.3 0.75 1.8 0.72
P (10 mm Hg) 0.89 0.56 0.82 0.66
R (10 beats/min) 1.3 0.63 1.2 0.62
ndex (10 U) 2.2 0.79 2.3 0.79
P  blood pressure; HR  heart rate; OR  odds ratio; other abbreviations as in
able 1.esult in greater heterogeneity among patients in clinicalractice than among subjects in clinical trials. As would be
xpected, there was a greater range of risk index values seen
mong the NRMI participants than among subjects in the
nTIME-II trial. For this reason, the risk index has been
pdated in this analysis, using the index as a continuous
ariable with a nomogram to estimate risk in clinical
ractice (Table 2). This updated version of the index
ontinues to perform well in the clinical trial population and
as an expanded range to better capture the range of
atients in a clinical population. Nonparticipants in clinical
rials tend to be at higher risk of adverse outcomes than
articipants. Our analysis from NRMI supports this impor-
ant observation. Specifically, patients in NRMI database
ere more likely to experience in-hospital death than those
nrolled in the InTIME-II trial (12.3% vs. 5.4%). However,
hen stratified by baseline risk, mortality rates were remark-
bly similar between patients enrolled in the clinical trial
nd those receiving RT in the community registry (Fig. 2).
he strong discriminatory performance and excellent cali-
ration of the index among patients treated with reperfusion
n NRMI indicate that it is likely to be useful in a
real-world” population. In patients managed without RT,
he risk index maintains reasonable discriminatory perfor-
ance (c statistic 0.71); however, the event rates are higher
han observed in patients receiving RT. This difference has
een observed previously in the assessment of other risk
rediction rules and appears to be related to the therapeutic
mpact of RT, as well as the effects of co-morbidities that
mpact eligibility for RT (25).
A previous analysis of this index using data from the
ardiovascular Cooperative Project (CCP) suggested that it
id not perform as well from a discriminatory perspective in
population of elderly patients (29). However, when
odeled as a continuous variable (which helps to minimize
he inherent restriction introduced by including only elderly
atients) in CCP, the index performed reasonably well (c
tatistic 0.71) (29), as observed in our present analysis. In
ddition, the index revealed a significant graded relationship
ith mortality across the risk groups.
Important differences exist between the populations stud-
ed (CCP, NRMI, InTIME-II), which may help to explain
ome of the dissimilarity between these analyses. In CCP,
atients were restricted to those over age 65 years. As a
esult, the population was a considerably older population
median age 76 years), as compared with the InTIME-II
rial (median age 61 years) or NRMI (67.6 years). In
ddition, a minority of patients (36%) in the CCP analysis
eceived RT—significantly less than either the InTIME-II
rial or the nationally representative NRMI (56%). Our
nalysis from the large NRMI registry addresses these two
mportant issues. Second, stratified by the use of RT, there
as, in fact, strong concordance between the observed event
ates in the elderly versus the general population across each
isk index group. Although the discriminatory capacity of
he risk index was modestly attenuated in the elderly, it is
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TIMI Risk Index in NRMI August 18, 2004:783–9ot surprising that a three-component risk score with one of
he variables limited to the highest range performed less well
n discriminating among this specific subgroup than among
he entire population in NRMI. We believe that this
imitation is acceptable in the context of using the simple
isk index as a tool for the initial rapid categorization of risk,
o be followed by updated risk assessment as additional
nformation becomes available.
Finally, there were differences in design between our
tudy and the CCP analysis. The CCP is a retrospective
nalysis of charts of patients identified with MI by the
nternational Classification of Diseases-Ninth Revision-
linical Modification codes (1994 to 1996). Data abstracted
rom billing records may misidentify patients with MI, and
etrospective chart analysis is limited by what is available in
medical chart, compared with prospective identification of
nformation, as performed in a clinical trial (InTIME-II), as
ell as the identification of patients by medical professionals
nd the recording of information either during or after
ospitalization in a registry (NRMI).
An interesting observation from the application of the
IMI risk index to NRMI population was the striking
ifferences in the proportion of patients receiving RT.
atients in the higher risk index groups (40) were only
0% as likely to receive RT as those in the lower risk groups.
here are likely multiple factors that explain this discrep-
ncy, including medical co-morbidities and patient prefer-
nce. We have observed previously that patients in NRMI
ho did not receive RT were more likely to have multiorgan
ailure, chronic renal failure, uncertainty regarding the
iagnosis of MI, and bleeding risk (25). These factors partly
ccounted for the higher mortality among patients who did
ot receive RT. In the present analysis, performance of the
isk index is also compared between the InTIME-II trial
nd the NRMI. It is expected that these same factors
ontribute to the higher mortality observed in patients in
RMI treated without RT. However, it is noteworthy that
t is this group with the highest mortality that may derive
he greatest absolute benefit from reperfusion, yet receive it
he least.
tudy limitations. The strengths of this analysis are the
arge number of patients and that NRMI reflects varying
ractice patterns in the U.S. The level of detail of reporting
o-morbid illness in this very large database is, by necessity,
ess than that available in a smaller clinical trial or in clinical
ractice. The TIMI risk index was designed to provide a
reliminary risk assessment during the first patient encoun-
er. It does not integrate the effects of treatment, care
etting, co-morbid illnesses (including those potentially
nvolved in reperfusion eligibility), or baseline medications
n outcome. Such information may be added to the risk
ssessment to update the initial evaluation. The index is
ased on initial inpatient data in both data sets. Although
he findings of our analysis are likely generalizable to the
rehospital setting, this application merits direct evaluation.
he present analysis was not designed to assess the mech-nism by which the index predicts mortality in these distinct
atient populations. The risk index likely integrates baseline
isk (age) with the hemodynamic effects of MI (HR and
BP). Additional evaluation in data sets in which more
etailed information is available regarding ventricular func-
ion, the extent of coronary artery disease, and the cause of
eath may help to elucidate the mechanisms by which the
ndex predicts mortality.
onclusions. A simple risk index that can be calculated
rom age and vital signs is predictive of in-hospital mortality
n a diverse group of patients presenting to U.S. hospitals
ith MI. This risk index could be used as a practical tool to
apidly risk-stratify patients with MI and could be applied
y paramedical personnel in the prehospital setting or at the
ime of hospital presentation. Additional research to focus
n the interaction between the TIMI risk index and
reatment response in STEMI could advance the utility of
his measure.
eprint requests and correspondence: Dr. Stephen D. Wiviott,
IMI Study Group, Brigham and Women’s Hospital, Cardiovascular
ivision, 75 Francis Street, Boston, Massachusetts 02115. E-mail:
wiviott@partners.org.
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